Tbx1 represses Mef2c gene expression and is correlated with histone 3 deacetylation of the anterior heart field enhancer

Disease Models & Mechanisms
Luna Simona PaneAntonio Baldini

Abstract

The TBX1 gene is haploinsufficient in 22q11.2 deletion syndrome (22q11.2DS), and genetic evidence from human patients and mouse models points to a major role of this gene in the pathogenesis of this syndrome. Tbx1 can activate and repress transcription, and previous work has shown that one of its functions is to negatively modulate cardiomyocyte differentiation. Tbx1 occupies the anterior heart field (AHF) enhancer of the Mef2c gene, which encodes a key cardiac differentiation transcription factor. Here, we show that increased dosage of Tbx1 correlates with downregulation of Mef2c expression and reduced acetylation of its AHF enhancer in cultured mouse myoblasts. Consistently, 22q11.2DS-derived and in vitro-differentiated human induced pluripotent stem cells (hiPSCs) expressed higher levels of MEF2C and showed increased AHF acetylation, compared with hiPSCs from a healthy donor. Most importantly, we show that in mouse embryos, loss of Tbx1 enhances the expression of the Mef2c-AHF-Cre transgene in a specific region of the splanchnic mesoderm, and in a dosage-dependent manner, providing an in vivo correlate of our cell culture data. These results indicate that Tbx1 regulates the Mef2c AHF enhancer by inducing histone deacetylation.

References

Mar 10, 2001·Nature Genetics·L A Jerome, V E Papaioannou
Mar 27, 2001·Nucleic Acids Research·H BrantjesH Clevers
Jan 11, 2002·Developmental Biology·C H MjaatvedtR R Markwald
Jun 4, 2004·Development·Huansheng XuAntonio Baldini
Jun 23, 2007·The Journal of Biological Chemistry·Henner F FarinAndreas Kispert
Feb 8, 2008·Genome Biology·Barbara H Jennings, David Ish-Horowicz
Mar 11, 2008·Developmental Biology·Jun LiaoBernice E Morrow
Sep 6, 2008·Nature Protocols·Julia LeschikMichel Pucéat
Jun 27, 2009·PloS One·F Gabriella FulcoliAntonio Baldini
Sep 12, 2009·Circulation Research·Li ChenAntonio Baldini
Oct 24, 2009·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Alessandra MorettiKarl-Ludwig Laugwitz
May 14, 2010·Experimental Biology and Medicine·Jason Z StollerJonathan A Epstein
Mar 1, 2012·Human Molecular Genetics·Luna Simona PaneAntonio Baldini
Sep 13, 2013·Journal of Proteome Research·Erin KaltenbrunFrank L Conlon
Jun 4, 2016·Nature Communications·Filomena Gabriella FulcoliAntonio Baldini
Jan 7, 2017·Current Topics in Developmental Biology·A BaldiniE Illingworth

❮ Previous
Next ❯

Citations

Jun 20, 2020·Heart Failure Reviews·Yannick J H J TaverneDaphne Merkus
Mar 30, 2021·Frontiers in Genetics·Xuefei YuanMichael D Wilson

❮ Previous
Next ❯

Datasets Mentioned

BETA
AY324098

Methods Mentioned

BETA
transgenic
transfection
immunoprecipitation
ChIP-seq
acetylation
co-immunoprecipitation
PCR
reverse transcription PCR
ChIP
electrophoresis

Software Mentioned

Leica

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Argentine Hemorrhagic Fever

Argentine hemorrhagic fever (AHF) is an endemo-epidemic disease caused by junín virus (JUNV), a member of the arenaviridae family. Discover the latest research on AHF here.

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused by a partial deletion of chromosome 22. Symptoms include heart defects, poor immune system function, a cleft palate, complications related to low levels of calcium in the blood, and delayed development. Discover the latest research on this disease here.